Ahmad Ozair,Hannah Wilding,Debarati Bhanja,Nicholas Mikolajewicz,Michael Glantz,Stuart A. Grossman,Arjun Sahgal,Emilie Le Rhun,Michael Weller,Tobias Weiss,Tracy T. Batchelor,Patrick Y. Wen,Daphne A. Haas-Kogan,Mustafa Khasraw,Roberta Rudà,Riccardo Soffietti,Philipp Vollmuth,Vivek Subbiah,Chetan Bettegowda,Lily C. Pham,Graeme F. Woodworth,Manmeet S. Ahluwalia,Alireza Mansouri

Abstract:Leptomeningeal metastatic disease (LMD), encompassing entities of 'meningeal carcinomatosis', neoplastic meningitis' and 'leukaemic/lymphomatous meningitis', arises secondary to the metastatic dissemination of cancer cells from extracranial and certain intracranial malignancies into the leptomeninges and cerebrospinal fluid. The clinical burden of LMD has been increasing secondary to more sensitive diagnostics, aggressive local therapies for discrete brain metastases, and improved management of extracranial disease with targeted and immunotherapeutic agents, resulting in improved survival. However, owing to drug delivery challenges and the unique microenvironment of LMD, novel therapies against systemic disease have not yet translated into improved outcomes for these patients. Underdiagnosis and misdiagnosis are common, response assessment remains challenging, and the prognosis associated with this disease of whole neuroaxis remains extremely poor. The dearth of effective therapies is further challenged by the difficulties in studying this dynamic disease state. In this Review, a multidisciplinary group of experts describe the emerging evidence and areas of active investigation in LMD and provide directed recommendations for future research. Drawing upon paradigm-changing advances in mechanistic science, computational approaches, and trial design, the authors discuss domain-specific and cross-disciplinary strategies for optimizing the clinical and translational research landscape for LMD. Advances in diagnostics, multi-agent intrathecal therapies, cell-based therapies, immunotherapies, proton craniospinal irradiation and ongoing clinical trials offer hope for improving outcomes for patients with LMD.

Leptomeningeal metastatic disease: new frontiers and future directions